Aiforia Technologies
3.92 EUR -0.76%Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of areas from oncology to neuroscience. Aiforia Technologies is headquartered in Finland.
Log in to see the recommendation and risk by Inderes
Latest research
Extensive report
Analyst
Latest videos
Financial calendar
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Sto-Rahoitus Oy | 5.8 % | 5.8 % |
Mikael Lundin | 5.0 % | 5.0 % |
Premium
This content is for our Premium customers only.
Insider Transactions
Insider | Date | Total value |
---|---|---|
Johan Lundin | 22.06.2023 | 495,750EUR |
Jukka Tapaninen | 30.12.2022 | 4,044EUR |
Premium
This content is for our Premium customers only.
Forum updates
Income statement
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Revenue | 0.8 | 1.0 | 1.6 | 2.4 | 4.3 | 8.1 | 14.2 | 26.2 |
growth-% | 32.9 % | 14.7 % | 64.9 % | 49.3 % | 80.1 % | 88.4 % | 75.1 % | 84.1 % |
EBITDA | -1.6 | -3.5 | -9.5 | -9.7 | -6.8 | -4.4 | -0.5 | 7.6 |
EBIT (adj.) | -2.6 | -4.7 | -11.8 | -12.9 | -11.4 | -10.2 | -6.9 | 0.8 |
EBIT | -2.6 | -4.7 | -11.8 | -12.9 | -11.4 | -10.2 | -6.9 | 0.8 |
Profit before taxes | -2.8 | -7.6 | -12.2 | -12.9 | -11.5 | -10.5 | -7.2 | 0.5 |
Net income | -2.8 | -7.6 | -12.2 | -12.9 | -11.5 | -10.5 | -7.2 | 0.5 |
EPS (adj.) | -0.14 | -0.29 | -0.47 | -0.50 | -0.44 | -0.39 | -0.26 | 0.02 |
growth-% | ||||||||
Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Dividend ratio |
Login required
This content is only available for logged in users
Profitability and return on capital
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
EBITDA-% | -189.8 % | -354.2 % | -593.3 % | -404.5 % | -157.8 % | -54.7 % | -3.2 % | 28.8 % |
EBIT-% (adj.) | -310.1 % | -481.4 % | -731.9 % | -537.1 % | -263.0 % | -125.4 % | -48.6 % | 3.0 % |
EBIT-% | -310.1 % | -481.4 % | -731.9 % | -537.1 % | -263.0 % | -125.4 % | -48.6 % | 3.0 % |
ROE | -386.3 % | -39.0 % | -36.2 % | -54.8 % | -95.0 % | -934.9 % | 93.4 % | -4.3 % |
ROI | -77.0 % | -20.9 % | -31.8 % | -45.4 % | -56.6 % | -60.3 % | -40.7 % | 4.8 % |
Login required
This content is only available for logged in users
Valuation
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Share price (EUR) | 5.22 | 3.23 | 3.49 | 3.92 | 3.92 | 3.92 | 3.92 | |
Shares | 20.0 | 25.8 | 25.8 | 26.0 | 26.4 | 27.2 | 27.5 | 27.5 |
Market cap | 134.6 | 83.4 | 90.6 | 103.3 | 106.8 | 107.7 | 107.8 | |
Enterprise value | 99.4 | 62.4 | 82.4 | 107.2 | 120.4 | 127.6 | 126.7 | |
EV/S | - | 102.0 | 38.9 | 34.4 | 24.8 | 14.8 | 9.0 | 4.8 |
EV/EBITDA | - | - | - | - | - | - | - | 16.8 |
EV/EBIT (adj.) | - | - | - | - | - | - | - | 163.6 |
EV/EBIT | - | - | - | - | - | - | - | 163.6 |
P/E (adj.) | - | - | - | - | - | - | - | 227.2 |
P/E | - | - | - | - | - | - | - | 227.2 |
P/B | - | 3.5 | 2.8 | 5.1 | 16.2 | - | - | - |
P/S | - | 138.2 | 51.9 | 37.8 | 23.9 | 13.1 | 7.6 | 4.1 |
Dividend yield | ||||||||
Equity ratio | 16.8 % | 86.4 % | 80.3 % | 63.5 % | 29.4 % | -17.2 % | -46.3 % | -40.4 % |
Gearing ratio | 146.0 % | -92.8 % | -71.6 % | -45.4 % | 60.6 % | -329.2 % | -175.2 % | -173.9 % |
Login required
This content is only available for logged in users
Quarter data
Q1/23 | Q2/23 | Q3/23 | Q4/23 | 2023 | Q1/24e | Q2/24e | Q3/24e | Q4/24e | |
---|---|---|---|---|---|---|---|---|---|
Revenue | 1.0 | 1.4 | 2.4 | 2.0 | 2.3 | ||||
EBITDA | -5.0 | -4.7 | -9.7 | -3.5 | -3.4 | ||||
EBIT | -6.4 | -6.5 | -12.9 | -5.5 | -5.8 | ||||
Profit before taxes | -6.5 | -6.4 | -12.9 | -5.6 | -5.9 | ||||
Net income | -6.5 | -6.4 | -12.9 | -5.6 | -5.9 |
Login required
This content is only available for logged in users
Aiforia signs a contract with a veterinary health company in the US
Richard Haworth joins Aiforia’s Scientific Advisory Board
Join Inderes community
Don't miss out - create an account and get all the possible benefits